GLP-1 Receptor Agonists: Pharmacological Rationale and Monitoring

GLP-1 receptor agonists mimic endogenous glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and increasing satiety. These actions improve glycemic control and promote weight loss. A key advantage is their low risk of hypoglycemia, especially vital for older adults and CKD patients. Common gastrointestinal side effects like nausea, vomiting, diarrhea, and constipation can be managed with gradual dose titration and patient education. Monitoring hydration is crucial for patients with advanced CKD to prevent kidney function deterioration.

A proposed treatment plan involves initiating semaglutide alongside continuing losartan for renal and cardiovascular protection. Ongoing monitoring includes assessing Hemoglobin A1C every three months until treatment goals are met, renal function every three to six months, and evaluating for gastrointestinal adverse effects, hydration status, pancreatitis, or gallbladder disease. Reinforcing medication adherence and diabetes self-management education is also important. For patients with specific conditions like CKD, an individualized A1C target, such as less than 8%, might be more appropriate than intensive glycemic control.